As of July 31, 2025, Caplin Point Laboratories Ltd (CAPLIPOINT) is trading near ₹2,085, showing a mixed but steady performance with some recent price fluctuations around this level. The stock briefly touched intraday highs around ₹2,095 and lows near ₹2,030, maintaining support in the ₹2,030–₹2,055 range. Market capitalization stands broadly near ₹15,590 crore.
Caplin Point benefits from solid fundamentals in the pharmaceutical sector, supported by consistent revenue growth and operational efficiencies. The price-to-earnings ratio sits around 29, while the price-to-book ratio is approximately 5.5, indicating premium valuation relative to book but in line with sector expectations. Dividend yield is low at about 0.15%, reflecting the company’s focus on growth over payout.
Technically, the stock tends to hover above its medium-term moving averages like the 50-day and 200-day SMAs, showing cautious bullish momentum, although near-term volatility remains. Trading volumes are moderate, and the relative strength index is near mid-range levels, suggesting balanced momentum without overbought or oversold extremes.
Overall, Caplin Point Laboratories currently reflects steady fundamentals with a valuation premium typical of its pharma peer group, supported by stable trading ranges and positive medium-term technical signals. The near-term outlook remains cautiously optimistic, with key support near ₹2,030 and potential resistance around ₹2,100–₹2,120.
Caplin Point benefits from solid fundamentals in the pharmaceutical sector, supported by consistent revenue growth and operational efficiencies. The price-to-earnings ratio sits around 29, while the price-to-book ratio is approximately 5.5, indicating premium valuation relative to book but in line with sector expectations. Dividend yield is low at about 0.15%, reflecting the company’s focus on growth over payout.
Technically, the stock tends to hover above its medium-term moving averages like the 50-day and 200-day SMAs, showing cautious bullish momentum, although near-term volatility remains. Trading volumes are moderate, and the relative strength index is near mid-range levels, suggesting balanced momentum without overbought or oversold extremes.
Overall, Caplin Point Laboratories currently reflects steady fundamentals with a valuation premium typical of its pharma peer group, supported by stable trading ranges and positive medium-term technical signals. The near-term outlook remains cautiously optimistic, with key support near ₹2,030 and potential resistance around ₹2,100–₹2,120.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.